| HOME >> BIOLOGY >> TECHNOLOGY |
ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.
ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArrayTM family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers and develops its own projects for the detection of other chronic diseases such as Alzheimer's disease or atherosclerosis.
In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.
Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005.
This press release includes only summary information and does not
purport to be comprehensive. The projections, forecast and estimates of
ExonHit Therapeutics which may be contained herein are for illustrative
purposes only and are based on management's current views and assumptions.
Such projections, forecast and estimates i
'/>"/>
| SOURCE ExonHit Therapeutics SA Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
6. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
7. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
8. Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
9. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
10. 3 strikes, youre out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause
11. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |